Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New CRM launches

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)

You may also be interested in...

Boston Scientific Sees CRM Pipeline Aiding ICD Market Share Gains

Boston Scientific is highlighting recent and near-term product introductions as a key component of its plan to boost market share in its cardiac rhythm management business

Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts